0A4D Stock Overview

A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. More details

0A4D fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 14.8% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Has less than 1 year of cash runway

Does not have a meaningful market cap ($16M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

Equillium, Inc. Competitors

Arecor Therapeutics

AIM:AREC

UK£14.3m

ProBiotix Health

OFEX:PBX

UK£13.4m

Tissue Regenix Group

AIM:TRX

UK£26.0m

SkinBioTherapeutics

AIM:SBTX

UK£49.5m

Price History & Performance

Summary of share price highs, lows and changes for Equillium
Historical stock prices
Current Share Price	US$0.48
52 Week High	US$1.87
52 Week Low	US$0.40
Beta	1.86
1 Month Change	-40.44%
3 Month Change	-28.36%
1 Year Change	-71.97%
3 Year Change	-84.66%
5 Year Change	n/a
Change since IPO	-91.44%

Recent updates

Shareholder Returns

	0A4D	GB Biotechs	GB Market
7D	6.4%	1.1%	4.7%
1Y	-72.0%	-17.7%	2.3%

Return vs Industry: 0A4D underperformed the UK Biotechs industry which returned -16.7% over the past year.

Return vs Market: 0A4D underperformed the UK Market which returned 2.7% over the past year.

Price Volatility

Is 0A4D's price volatile compared to industry and market?
0A4D volatility
0A4D Average Weekly Movement	25.1%
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.6%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	3.2%

Stable Share Price: 0A4D's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0A4D's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2017	35	Bruce Steel	www.equilliumbio.com

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma.

Equillium, Inc. Fundamentals Summary

How do Equillium's earnings and revenue compare to its market cap?
0A4D fundamental statistics
Market cap	US$16.83m
Earnings (TTM)	-US$8.07m
Revenue (TTM)	US$41.10m

0.4x

P/S Ratio

-2.1x

P/E Ratio

Is 0A4D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4D income statement (TTM)
Revenue	US$41.10m
Cost of Revenue	US$0
Gross Profit	US$41.10m
Other Expenses	US$49.16m
Earnings	-US$8.07m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.23
Gross Margin	100.00%
Net Profit Margin	-19.63%
Debt/Equity Ratio	0%

How did 0A4D perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/18 15:13
End of Day Share Price	2025/04/14 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Equillium, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	H.C. Wainwright & Co.
Biren Amin	Jefferies LLC
Catherine Novack	JonesTrading Institutional Services, LLC

0A4D Stock Overview

Rewards

Risk Analysis

Equillium, Inc. Competitors

AIM:AREC

UK£14.3m

OFEX:PBX

UK£13.4m

AIM:TRX

UK£26.0m

AIM:SBTX

UK£49.5m

Price History & Performance

Recent News & Updates

Equillium, Inc., Annual General Meeting, May 21, 2025

Full year 2024 earnings released: US$0.23 loss per share (vs US$0.38 loss in FY 2023)

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium and Biocon Limited Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

High number of new directors

Equillium, Inc. Announces Board and Committee Changes

Recent updates

Equillium, Inc., Annual General Meeting, May 21, 2025

Full year 2024 earnings released: US$0.23 loss per share (vs US$0.38 loss in FY 2023)

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium and Biocon Limited Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

High number of new directors

Equillium, Inc. Announces Board and Committee Changes

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

New minor risk - Profitability

Forecast to breakeven in 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Insufficient new directors

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Insufficient new directors

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

High number of new directors

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

High number of new directors

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Forecast to breakeven in 2025

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience